You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Some of the market's most influential voices, including Kári Stefánsson and Linda Avey, believe that consumer genomics is not on the way out but rather experiencing a period of transition.
CNBC discusses factors contributing to the state of direct-to-consumer genetic testing.
CEO Margo Georgiadis said that the company has "seen a slowdown in consumer demand across the entire DNA category."
The FDA has been prodding labs performing pharmacogenetic testing, and software firms providing reports from such testing, to undergo regulatory review.
Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.
The layoffs occurred across 23andMe's consumer business, which is being restructured, but did not impact its therapeutics business.
Bloomberg reports that 23andMe has licensed an antibody it developed to treat inflammatory diseases to a Spanish drugmaker.
As 2020 dawns, forensic genomics is poised for growth as companies aim to harness the power of consumer databases coupled with advances in sequencing.
According to Yahoo News, the Pentagon is warning members of the military that direct-to-consumer DNA testing kits might raise security risks.
Consumer Reports examines the complexities of giving a DNA testing kit as a holiday gift.
A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.
Nature News writes that viral genomic surveillance in the US faces systemic issues.
President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.
In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.